The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD
Patients who have met the criteria for COPD GOLD B defined by an exacerbation not more than 1 time in the last year prior to the study enrollment. These patients will be recruited in sequential sequence.
Patients with COPD GOLD B are previously treated with either LAMA or LAMA/LABA or short-acting bronchodilators
Patients who are able to provide informed consent.
You may not be if
\- Concomitant with active and old pulmonary TB, lung cancer, bronchiectasis, lung fibrosis, destroyed lung, other malignancy, active heart diseases.
Receiving long-term treatment with immunosuppressive drugs and systemic corticosteroids
Being treated with triple therapy (ICS/LABA/LAMA)
Being in terminally ill conditions
Clareo Health | The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD
